Get the Stockscreener App
3.06
3.73%
0.11
Anixa Biosciences Inc stock is traded at $3.06, with a volume of 57,081.
It is up +3.73% in the last 24 hours and down -8.25% over the past month.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
See More
Previous Close:
$2.95
Open:
$2.96
24h Volume:
57,081
Relative Volume:
0.42
Market Cap:
$98.57M
Revenue:
-
Net Income/Loss:
$-12.48M
P/E Ratio:
-7.8462
EPS:
-0.39
Net Cash Flow:
$-7.93M
1W Performance:
+3.03%
1M Performance:
-8.25%
6M Performance:
-0.65%
1Y Performance:
-2.86%
1-Day Range:
$2.96
$3.09
1-Week Range:
$2.92
$3.09
52-Week Range:
$2.07
$4.20
Anixa Biosciences Inc Stock (ANIX) Company Profile
Name
Anixa Biosciences Inc
Sector
Industry
Phone
408-708-9808
Address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE
Compare ANIX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIX
Anixa Biosciences Inc
|
3.06 | 95.99M | 0 | -12.48M | -7.93M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Anixa Biosciences Inc Stock (ANIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Maxim Group | Buy |
| Dec-23-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-12-21 | Initiated | H.C. Wainwright | Buy |
Anixa Biosciences Inc Stock (ANIX) Latest News
Anixa Biosciences, Inc Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology - MarketScreener
Anixa biosciences secures Chinese patent for breast cancer vaccine - Investing.com
First-Ever Chinese Patent Granted: Anixa's Revolutionary Breast Cancer Vaccine Targets World's Largest Market - Stock Titan
Anixa Biosciences: Buy Rating Reiterated, Price Target Raised to $10 - AInvest
Anixa Biosciences shares rise 1.89% intraday after treating second patient in fourth cohort of ovarian cancer CAR-T clinical trial. - AInvest
Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort - TipRanks
30x Dose Increase Shows No Toxicity: Anixa's Novel Ovarian Cancer CAR-T Therapy Reaches Major Milestone - Stock Titan
Can Anixa Biosciences Inc. continue delivering strong returns2025 Technical Patterns & High Return Trade Opportunity Guides - thegnnews.com
Combining price and volume data for Anixa Biosciences Inc.2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Is this a good reentry point in Anixa Biosciences Inc.2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser
Is Anixa Biosciences Inc. benefiting from interest rate changesJuly 2025 Trade Ideas & Proven Capital Preservation Tips - thegnnews.com
Will Anixa Biosciences Inc. outperform the market in YEAR2025 Market Outlook & Fast Exit Strategy with Risk Control - thegnnews.com
Anixa Biosciences Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Volatility Report & Community Verified Trade Alerts - sundaytimes.kr
Anixa Biosciences Bets On Cancer Vaccines And CAR-T Trials - Finimize
Can Anixa Biosciences Inc. sustain its profitabilityJuly 2025 PostEarnings & Free Community Consensus Stock Picks - thegnnews.com
Anixa Biosciences Inc. Forms Bullish Flag — Upside Ahead2025 Top Gainers & Weekly Breakout Opportunity Watchlist - sundaytimes.kr
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - BioSpace
Anixa Biosciences Receives Patent Extension for CAR-T Technology - AInvest
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
Anixa Biosciences Receives Additional US Patent for CAR-T Technology, Extending Protection to 2045 - AInvest
Anixa Biosciences secures new patent for solid tumor CAR-T technology - Investing.com India
Anixa Biosciences secures new patent for solid tumor CAR-T technology By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Issuance Of Additional U.S. Patent For CAR-T Technology - Barchart.com
Tools to assess Anixa Biosciences Inc.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
Anixa Biosciences shares rise 1.68% after-hours as Dr. Wenham to present at Ovarcoming Cancer Conference. - AInvest
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - The Malaysian Reserve
Breakthrough CAR-T Therapy for Ovarian Cancer: Moffitt's Chair Reveals Latest Trial Progress at Major Conference - Stock Titan
What momentum shifts mean for Anixa Biosciences Inc.Free Daily Volume Spike Trading Signals - Newser
D. Boral Capital Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX) - Defense World
Competitive Positioning of Anixa Biosciences Inc.: Is It Leading or LaggingPortfolio Positioning Strategy With Timing - Newser
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial - BioSpace
Director Makes Bold Move with Major Stock Purchase in Anixa Biosciences - TipRanks
Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating - TipRanks
Anixa plans to begin Phase 2 of breast cancer vaccine trial - TipRanks
Anixa Biosciences director Titterton buys $30k in stock By Investing.com - Investing.com Canada
Anixa Biosciences director Titterton buys $30k in stock - Investing.com India
Breakthrough Breast Cancer Vaccine Achieves 70% Immune Response, FDA Clears Path for Phase 2 Trial - Stock Titan
How does Anixa Biosciences Inc. compare to its industry peersStrong return on assets - Jammu Links News
What is Anixa Biosciences Inc. company’s growth strategyTriple-digit growth rates - Jammu Links News
How many analysts rate Anixa Biosciences Inc. as a “Buy”Turn volatility into profit opportunities - Jammu Links News
Is Anixa Biosciences Inc. stock overvalued or undervaluedTurn volatility into profit opportunities - Jammu Links News
What is the dividend policy of Anixa Biosciences Inc. stockCapitalize on momentum stocks early - Jammu Links News
What are analysts’ price targets for Anixa Biosciences Inc. in the next 12 monthsDiscover high-impact stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Anixa Biosciences Inc.Free Investment Risk Control - Jammu Links News
When is Anixa Biosciences Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Why is Anixa Biosciences Inc. stock attracting strong analyst attentionGet real-time updates on market movers - Jammu Links News
Should I hold or sell Anixa Biosciences Inc. stock in 2025Turn volatility into profit opportunities - Jammu Links News
What catalysts could drive Anixa Biosciences Inc. stock higher in 2025Unlock powerful stock screening tools - Jammu Links News
How does Anixa Biosciences Inc. generate profit in a changing economyAchieve rapid growth with smart investments - Jammu Links News
RSI Crosses Above 30 for Anixa Biosciences Inc. — Reversal in SightWeekly Top Gainers Forecast Watchlist Released - metal.it
Anixa Biosciences Secures Canadian Patent for Breast Cancer Vaccine Technology - AInvest
Anixa Biosciences Inc Stock (ANIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Anixa Biosciences Inc Stock (ANIX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KUMAR AMIT | Chief Executive Officer |
Jul 30 '25 |
Buy |
3.16 |
5,000 |
15,800 |
579,925 |
| Baskies Arnold M | Director |
Jul 18 '25 |
Buy |
3.39 |
5,000 |
16,950 |
125,000 |
| Titterton Lewis H jr | Director |
Jul 11 '25 |
Buy |
3.14 |
10,000 |
31,400 |
943,334 |
| KUMAR AMIT | Chief Executive Officer |
Jul 11 '25 |
Buy |
3.15 |
5,000 |
15,750 |
574,925 |
| KUMAR AMIT | Chief Executive Officer |
Jun 04 '25 |
Buy |
2.85 |
10,000 |
28,500 |
569,925 |
| Baskies Arnold M | Director |
Jan 28 '25 |
Buy |
2.82 |
5,000 |
14,100 |
120,000 |
| Titterton Lewis H jr | Director |
Jan 23 '25 |
Buy |
2.91 |
2,000 |
5,820 |
932,334 |
| Titterton Lewis H jr | Director |
Jan 24 '25 |
Buy |
3.00 |
1,000 |
3,000 |
933,334 |
| Titterton Lewis H jr | Director |
Jan 22 '25 |
Buy |
3.01 |
2,000 |
6,020 |
930,334 |
| Titterton Lewis H jr | Director |
Jan 21 '25 |
Buy |
2.59 |
6,000 |
15,540 |
928,334 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):